Ipamorelin: The Selective GHRP — Mechanism, Benefits & Research Overview

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide — a five-amino-acid chain with the sequence Aib-His-D-2Nal-D-Phe-Lys-NH₂ — belonging to the growth hormone releasing peptide (GHRP) family. It acts as a selective agonist at the ghrelin receptor (GHSR-1a), the same receptor activated by the "hunger hormone" ghrelin, triggering pulsatile growth hormone secretion from the anterior pituitary [1].

Developed by Novo Nordisk under the research designation NNC 26-0161, Ipamorelin emerged from systematic efforts to find the cleanest possible GH secretagogue. First- and second-generation GHRPs (GHRP-6, GHRP-2) effectively raised GH but came with off-target stimulation of ACTH, cortisol, and prolactin — side effects that complicate long-term research protocols. Ipamorelin, the third-generation GHRP, was specifically engineered to retain the GH-stimulating signal while stripping away those unwanted hormonal activations [1].

With a molecular weight of approximately 711 Da and a plasma half-life of roughly two hours, Ipamorelin occupies a practical middle ground: short enough to preserve natural pulsatility, long enough to support once-daily or twice-daily injection protocols. Its selectivity profile — potent GH release, minimal cortisol/prolactin elevation — is what distinguishes it from every other GHRP studied to date [1][3].

How it works: mechanism of action

Ipamorelin's mechanism centres on one receptor: the growth hormone secretagogue receptor type 1a (GHSR-1a), also known as the ghrelin receptor. When Ipamorelin binds GHSR-1a on pituitary somatotrophs, it triggers a G-protein-coupled signalling cascade that culminates in calcium mobilisation and growth hormone exocytosis — a distinct pathway from the GHRH receptor (GHRH-R) [1][6].

The CJC-1295 synergy: two receptors, one amplified pulse

This dual-receptor reality is what makes the Ipamorelin + CJC-1295 No DAC combination so extensively studied. CJC-1295 No DAC is a GHRH analogue: it primes the somatotroph by activating GHRH-R and increasing intracellular cAMP. Ipamorelin simultaneously activates GHSR-1a via a calcium-dependent pathway. Because the two compounds act through entirely different receptor systems, their signals are additive — the resulting GH pulse is substantially larger than either agent alone could produce [1][3].

Selectivity: why Ipamorelin stands apart

Earlier GHRPs (particularly GHRP-6 and GHRP-2) activated not only GHSR-1a but also downstream pathways that stimulate ACTH release — leading to cortisol and prolactin elevation. Raun et al.'s landmark 1998 characterisation of Ipamorelin showed that at equi-efficacious GH-stimulating doses, Ipamorelin produced no statistically significant increase in cortisol or prolactin in pituitary cell cultures and rat models, a finding that was robust across a wide dose range [1]. This GH-selective mechanism is Ipamorelin's defining pharmacological property.

Pulsatility preservation

Unlike growth hormone itself (exogenous rhGH), Ipamorelin does not suppress the hypothalamic–pituitary axis feedback loop. It stimulates GH release within the existing pulse architecture, working with somatostatin cycles rather than overriding them. This means GH secretion remains pulsatile — physiologically closer to natural patterns — rather than creating the flat supraphysiological GH elevation associated with direct rhGH administration [1][6].

Documented research benefits

The following benefits have been documented in preclinical studies, primarily in rodent models. The human evidence base for Ipamorelin specifically is limited, though the broader GHRP and GH secretagogue literature provides supporting context.

GH and IGF-1 elevation with high selectivity

Ipamorelin's primary and most reproducible research finding is dose-dependent GH release with minimal off-target hormonal activation. In Raun et al. (1998), Ipamorelin stimulated GH secretion in rat pituitary cells with a potency comparable to GHRP-6 but without the ACTH/cortisol activation that made GHRP-6 problematic for chronic protocols [1]. Secondary IGF-1 elevation follows the GH pulse and is well-documented across GH secretagogue literature [4].

Body composition: lean mass increase and fat reduction

Elevated GH and IGF-1 signalling promotes protein synthesis and lipolysis. In rodent studies, sustained GH secretagogue treatment — including Ipamorelin protocols — produced measurable increases in lean body mass and reductions in adipose tissue. The selectivity advantage is relevant here: because cortisol is not elevated, the muscle-sparing / anabolic signal is not offset by the catabolic glucocorticoid burden seen with non-selective GHRPs [1][4].

Bone mineral density

Svensson et al. (2000) studied the effects of GH secretagogue treatment in an ovariectomised rat model of osteoporosis, finding that Ipamorelin at doses of 75–300 µg/kg/day SC significantly increased bone formation markers and improved bone mineral density compared to controls [2]. This bone-anabolic effect is consistent with GH and IGF-1's established roles in osteoblast stimulation and skeletal remodelling.

Sleep quality and recovery

The largest physiological GH pulse in healthy individuals occurs during slow-wave sleep. Ipamorelin's ~2-hour half-life is well-suited to pre-sleep administration — it initiates and amplifies the natural nocturnal GH pulse rather than disrupting it. The downstream effects on tissue repair, protein synthesis, and cellular recovery that occur during sleep-related GH release are well-established in the broader growth hormone literature [3][4].

No significant appetite stimulation

GHRP-6 is well-known to dramatically increase appetite — an effect driven by ghrelin-like activity at hypothalamic feeding centres. Despite also being a ghrelin receptor agonist, Ipamorelin does not replicate this effect at research doses. This is a meaningful practical advantage for body composition research: researchers can study GH-axis effects without the confounding variable of increased caloric intake [1].

Dosing ranges in published literature

The pivotal Ipamorelin characterisation studies used rodent models. Human-equivalent dose translation requires body-surface-area allometric scaling and carries substantial uncertainty. The GHRP class literature provides some human-context dosing data but these are not validated clinical guidelines.

The 200–300 µg per injection range cited in human-context GHRP literature reflects general class dosing data, not Ipamorelin-specific Phase III trials. The important distinction from GHRP-6 and GHRP-2 is that Ipamorelin's clean selectivity means the limiting factor at higher doses is water retention / GH-related effects rather than cortisol-driven catabolic burden [1][3].

Administration routes & reconstitution

Routes studied in preclinical literature

• Subcutaneous (SC) — primary route in all major Ipamorelin studies; consistent, reproducible absorption
• Intramuscular (IM) — also studied; similar pharmacokinetics to SC
• Intraperitoneal (IP) — used in some rodent models; not applicable to humans

Timing: aligning with natural GH pulsatility

Pre-sleep administration is the most common protocol in research literature. This approach aligns Ipamorelin's ~2-hour peak with the natural nocturnal GH pulse that occurs in the first hours of slow-wave sleep, potentially amplifying a physiological process rather than overriding it. Some protocols include a second injection 30–60 minutes pre-training.

CJC-1295 No DAC pairing

When combining Ipamorelin with CJC-1295 No DAC, the two peptides are typically co-injected (same syringe or sequential same-site injection). The GHRH analogue (CJC-1295) primes the somatotroph via GHRH-R while Ipamorelin simultaneously activates GHSR-1a — the combined GH pulse is substantially larger than either compound alone [1][3].

Reconstitution protocol (lyophilised powder)

Ipamorelin is supplied as a lyophilised (freeze-dried) white powder. Standard laboratory reconstitution uses bacteriostatic water (0.9% benzyl alcohol in sterile water for injection).

1. Allow the vial to reach room temperature before opening
2. Add bacteriostatic water slowly down the side of the vial — do not inject directly onto the powder
3. Gently swirl; do not vortex or shake
4. Store reconstituted solution at 2–8°C, protected from light
5. Use within 28 days of reconstitution

Side effects and safety data

Ipamorelin's defining clinical characteristic — beyond its GH selectivity — is its exceptionally clean tolerability profile. The strategic removal of cortisol and prolactin stimulation eliminates the most clinically relevant adverse effects of older GHRPs, leaving a residual side-effect profile that is modest by comparison.

Reported adverse effects in literature

• Transient flushing or tingling — mild, brief, reported in some research subjects around the time of injection; resolves within minutes
• Mild headache — occasional; likely related to transient GH-mediated vasodilation
• Water retention — at higher GH elevations, mild peripheral oedema can occur; a class effect of GH secretagogues
• No significant cortisol elevation — this distinguishes Ipamorelin from GHRP-6 and GHRP-2; the absence of cortisol activation is verified across multiple preclinical studies [1]
• No significant prolactin elevation — similarly verified; prolactin-related adverse effects (libido disruption, galactorrhoea) are not a concern at research doses [1]
• No documented appetite increase — unlike GHRP-6, Ipamorelin does not produce meaningful ghrelin-mediated hunger stimulation at research doses [1]

What the safety data does not yet tell us

Human long-term safety data for Ipamorelin specifically are limited. The GHRP class has a generally well-characterised short-term profile, but chronic use studies at human-equivalent doses are absent. Patients with active malignancy, acromegaly-risk conditions, or pituitary disorders represent theoretical contraindication populations based on GH pathway pharmacology.

Interactions & contraindications

• CJC-1295 No DAC (synergistic) — the most well-studied combination; GHRH-R activation (CJC-1295) + GHSR-1a activation (Ipamorelin) produces an amplified GH pulse; this is the primary reason Ipamorelin is so frequently studied in this combination [1][3]
• GHRP-6 or GHRP-2 (additive but redundant) — combining two GHRPs acting at the same receptor (GHSR-1a) produces marginal additive benefit at best; there is no pharmacological rationale and the cortisol/prolactin liability of GHRP-6/GHRP-2 would be reintroduced
• Glucocorticoids (antagonistic) — exogenous corticosteroids blunt GH response by multiple mechanisms; co-administration with Ipamorelin would be expected to reduce GH stimulatory efficacy
• Somatostatin analogues (antagonistic) — directly oppose GH release at the pituitary level; would substantially attenuate Ipamorelin's effect
• Insulin / hypoglycaemics — GH has counter-regulatory effects on insulin; elevated GH from Ipamorelin could modestly reduce insulin sensitivity; relevant consideration in diabetic research subjects

Storage & stability

Frequently asked questions

What makes Ipamorelin different from GHRP-6?

Both are ghrelin receptor agonists that stimulate GH secretion, but their side-effect profiles are starkly different. GHRP-6 significantly elevates cortisol and prolactin alongside GH, and produces a pronounced increase in appetite via hypothalamic ghrelin signalling. Ipamorelin produces comparable GH stimulation with no meaningful cortisol, prolactin, or appetite elevation — a selectivity advantage that is directly attributable to its engineered molecular structure [1]. For researchers whose protocols require clean GH-axis stimulation without glucocorticoid confounding, Ipamorelin is the preferred GHRP.

Should Ipamorelin always be paired with CJC-1295?

Not necessarily — Ipamorelin produces meaningful GH stimulation as a standalone agent. However, the combination with CJC-1295 No DAC is the most widely studied protocol because the two peptides act via entirely different receptor systems (GHSR-1a vs. GHRH-R), and their combined GH pulse is significantly larger than either alone. For research protocols targeting maximal GH and IGF-1 elevation, the combination is well-supported by the literature [1][3].

Does Ipamorelin cause hunger?

No — this is one of Ipamorelin's key advantages over GHRP-6. Despite binding the ghrelin receptor (which is involved in appetite regulation), Ipamorelin does not produce the strong hunger signal characteristic of GHRP-6 at equivalent GH-stimulating doses. The molecular determinants of appetite stimulation and GH stimulation through GHSR-1a appear separable, and Ipamorelin's structure selectively captures the GH signal [1].

How quickly does Ipamorelin raise GH levels?

GH release following Ipamorelin injection is rapid — peak plasma GH occurs within approximately 15–30 minutes in rodent models, consistent with the pharmacokinetics of other GHRPs. The pulse is transient (returning toward baseline within 2–3 hours), which preserves the natural episodic character of GH secretion rather than creating sustained supraphysiological elevation [1].

Is Ipamorelin legal in India?

Ipamorelin is not an approved pharmaceutical in India and is not scheduled under the Drugs and Cosmetics Act 1940 as a restricted substance. It is sold as a research compound for laboratory use. Importation, sale, or use as a therapeutic agent would require appropriate regulatory approval. Purchasing for legitimate research purposes is not prohibited. See our introductory peptide guide for a fuller discussion of the Indian regulatory context.